Brian Huh, MD
Rheumatology · Los Angeles, CANPI 1275614455
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $60,754 of the $90,760 with a category attached, or 66.9%. 29 manufacturers reported payments, led by Amgen at 58.6% of the total. Reporting peaked in 2019 at $49,682 and has fallen 94.8% since, to $2,585 in 2025. Among rheumatology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 966 payments — averaging $93.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$53K
- Sanofi$13K
- Regeneron$7K
- AbbVie$4K
- Regeneron Healthcare Solutions, Inc.$3K
- Pfizer$2K
- plus $8K from 23 others
What the payments were for
- Consulting fees$5,4006%
- Speaking & faculty fees$60,75467%
- Travel & lodging$2,6113%
- Food & beverage$21,94724%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 255 | $53,147 |
| Sanofi | 42 | $13,455 |
| Regeneron | 11 | $6,669 |
| AbbVie | 206 | $4,108 |
| Regeneron Healthcare Solutions, Inc. | 11 | $3,476 |
| Pfizer | 68 | $1,593 |
| UCB, Inc. | 69 | $1,583 |
| Johnson & Johnson(2 entities) | 68 | $1,262 |
| AstraZeneca(2 entities) | 45 | $1,210 |
| GSK | 45 | $925 |
| Lilly USA, LLC | 41 | $754 |
| Zimmer Biomet | 14 | $529 |
| Ferring Pharmaceuticals Inc. | 24 | $266 |
| Novartis | 13 | $264 |
| Radius Health, Inc. | 13 | $239 |
| Mallinckrodt Enterprises LLC | 8 | $205 |
| Aurinia Pharma U.S., Inc. | 3 | $167 |
| Mallinckrodt Hospital Products Inc. | 5 | $146 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $131 |
| Amarin Pharma, Inc. | 1 | $126 |
| Boehringer Ingelheim | 4 | $94 |
| ANI Pharmaceuticals, Inc. | 3 | $81 |
| Sobi, Inc | 3 | $77 |
| Sanofi-aventis U.S. LLC | 2 | $76 |
| Celltrion USA Inc. | 2 | $47 |
| Genentech USA, Inc. | 3 | $47 |
| Shire North American Group Inc | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Almatica Pharma LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$90,760 in reported general payments places this provider in the 90th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 313 | $1,909,616 |
| Enbrel SureclickEtanercept | 109 | $795,438 |
| ProliaDenosumab | 421 | $689,450 |
| Xeljanz XrTofacitinib Citrate | 112 | $622,084 |
| Humira(Cf) PenAdalimumab | 57 | $474,654 |
| Enbrel MiniEtanercept | 29 | $206,430 |
| Orencia ClickjectAbatacept | 24 | $134,088 |
| Cimzia (2 Pack)Certolizumab Pegol | 20 | $110,399 |
| XeljanzTofacitinib Citrate | 16 | $107,337 |
| OtezlaApremilast | 22 | $106,133 |
| OlumiantBaricitinib | 38 | $100,872 |
| Humira(Cf)Adalimumab | 13 | $88,139 |
| Humira PenAdalimumab | 12 | $77,573 |
| SimponiGolimumab | 12 | $71,965 |
| Teriparatide | 26 | $52,693 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf), Creon | $4,108 | $2,012,228338 claims |
| AmgenProlia, Otezla, Evenity (2 Syringes) | $53,147 | $833,354460 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,583 | $110,39920 claims |
| PfizerXeljanz | $1,593 | $107,33716 claims |
| Lilly USA, LLCOlumiant | $754 | $100,87238 claims |
| Johnson & JohnsonSimponi | $1,262 | $71,96512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 808 rheumatology providers in California.
Other rheumatology in Los Angeles
- Haoling WengLos Angeles$562K
- Glenn EhresmannLos Angeles$450K
- Elizabeth VolkmannLos Angeles$400K
- Daniel ArkfeldLos Angeles$378K
- Maureen McMahonLos Angeles$374K
- Leanna WiseLos Angeles$286K
- Jon GilesLos Angeles$248K
- Christina Charles-SchoemanLos Angeles$231K
- Karina Marianne TorralbaLos Angeles$142K
- Thomas RomanoLos Angeles$131K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.